BG96324A - Фармакологично активно вещество врс, метод за неговото получаване и терапевтичното му приложение - Google Patents

Фармакологично активно вещество врс, метод за неговото получаване и терапевтичното му приложение

Info

Publication number
BG96324A
BG96324A BG096324A BG9632492A BG96324A BG 96324 A BG96324 A BG 96324A BG 096324 A BG096324 A BG 096324A BG 9632492 A BG9632492 A BG 9632492A BG 96324 A BG96324 A BG 96324A
Authority
BG
Bulgaria
Prior art keywords
vrs
obtainment
active substance
therapeutic application
lyophilized
Prior art date
Application number
BG096324A
Other languages
English (en)
Other versions
BG61191B1 (bg
Inventor
Predrag Sikiric
Marijan Petek
Ivo Rotkvic
Stjepan Mise
Simun Krizanac
Ivan Udovicic
Ernest Suchanek
Marko Duvnjak
Jerka Jukic
Original Assignee
Ernest Suchanek
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP90119376A external-priority patent/EP0432400B1/en
Application filed by Ernest Suchanek filed Critical Ernest Suchanek
Publication of BG96324A publication Critical patent/BG96324A/bg
Publication of BG61191B1 publication Critical patent/BG61191B1/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)

Abstract

1. Метод за получаване на телесно защитно вещество врс от човешки или животински стомашен сок, характеризиращ се със следните етапи на производство: събраният и хомогенизиран животински или човешки стомашен сок се разделя на твърди части и течна супернатанта чрез центрофугиране; течната супернатанта се диализира и лиофилизира; сухият остатък се пречиства през хроматографска колона, напълнена със слабо алкална, модифицирана йонообменна смола или гел; концентратът отново се диализира и лиофилизира; сухият остатък се пречиства чрез гел-хроматография; веществото врс се получава накрая от концентрата при използване на диализа и лиофилизация. 6 претенции
BG96324A 1990-09-11 1992-05-11 Методът за получаване на телесно защитно вещество ВРС от човешки или животински стомашен сок, се характеризира със следните етапи на производство: събраният и хомогенизиран животински или човешки стомашен сок се разделя на твърди части и течна супернатанта чрез центрофугиране; течната супернатанта се диализира и лиофилизира; сухият остатък се пречиства през хроматографска колона, напълнена със слабо алкална, модифицирана йонообменна смола или гел; концентратът отново се диализира и лиофилизира; сухият остатък се пречиства чрез гел- хроматография; веществото ВРС се получава накрая от концентрата при използване на диализа и лиофилизация. BG61191B1 (bg)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP9001533 1990-09-11
EP90119376A EP0432400B1 (en) 1989-09-12 1990-09-11 Pharmacologically active substance BPC, the process for its preparation and its use in the therapy
PCT/EP1990/001896 WO1992004368A1 (en) 1990-09-11 1990-11-13 Pharmacologically active substance bpc, the process for its preparation and its use in the therapy

Publications (2)

Publication Number Publication Date
BG96324A true BG96324A (bg) 1993-12-24
BG61191B1 BG61191B1 (bg) 1997-02-28

Family

ID=26069797

Family Applications (1)

Application Number Title Priority Date Filing Date
BG96324A BG61191B1 (bg) 1990-09-11 1992-05-11 Методът за получаване на телесно защитно вещество ВРС от човешки или животински стомашен сок, се характеризира със следните етапи на производство: събраният и хомогенизиран животински или човешки стомашен сок се разделя на твърди части и течна супернатанта чрез центрофугиране; течната супернатанта се диализира и лиофилизира; сухият остатък се пречиства през хроматографска колона, напълнена със слабо алкална, модифицирана йонообменна смола или гел; концентратът отново се диализира и лиофилизира; сухият остатък се пречиства чрез гел- хроматография; веществото ВРС се получава накрая от концентрата при използване на диализа и лиофилизация.

Country Status (6)

Country Link
JP (1) JP2591875B2 (bg)
AU (1) AU6901191A (bg)
BG (1) BG61191B1 (bg)
HU (1) HU217541B (bg)
RU (1) RU2104704C1 (bg)
WO (1) WO1992004368A1 (bg)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100488038B1 (ko) * 1997-05-23 2005-05-09 프레드라그 시키릭 기관 보호 활성을 지닌 신규한 신체 보호 화합물 펩티드염, 이의 제조 방법 및 치료에서의 이의 용도
RU2179858C1 (ru) * 2001-02-28 2002-02-27 Цыпин Анатолий Борисович Эндоскопическая спленотерапия гастродуоденальных язв
RU2207149C2 (ru) * 2001-04-04 2003-06-27 Закрытое Акционерное Общество Производственное Предприятие "Эндо-Фарм-А" Способ профилактики и лечения желчекаменной болезни
RU2189830C1 (ru) * 2001-05-21 2002-09-27 Общество с ограниченной ответственностью Фирма "ЭЙКОСЪ" Биологически активная добавка "лактогон"
KR20030067435A (ko) * 2002-02-06 2003-08-14 유지고하라 에너지변환극판과 그 제법
KR20030076007A (ko) * 2002-03-22 2003-09-26 유지고하라 복수자계에 의한 열에너지의 변환장치
US10350293B2 (en) 2016-08-23 2019-07-16 Pharmacotherapia d.o.o. Compositions and methods for treating symptoms associated with multiple sclerosis
CN114632092B (zh) * 2022-05-17 2022-08-23 北京第一生物化学药业有限公司 睾丸片在制备具有降糖活性的药物中的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1279820A (en) * 1968-12-26 1972-06-28 Nissui Pharm Co Ltd Process for preparing mucoprotein and product obtained thereby

Also Published As

Publication number Publication date
RU2104704C1 (ru) 1998-02-20
AU6901191A (en) 1992-03-30
JPH05503089A (ja) 1993-05-27
HUT61320A (en) 1992-12-28
HU217541B (hu) 2000-02-28
WO1992004368A1 (en) 1992-03-19
JP2591875B2 (ja) 1997-03-19
HU9201941D0 (en) 1992-09-28
BG61191B1 (bg) 1997-02-28

Similar Documents

Publication Publication Date Title
ES2019956B3 (es) Procedimiento de eliminacion del colesterol contenido en una materia grasa de origen animal, y la materia grasa empobrecida en colesterol obtenida.
PH18520A (en) Heterocyclic carboxamides,compositions containing such compounds and methods of treatment therewith
EP0804734A4 (en) PROTEIN COUPLED STERILE AND APYROGEN FOR BINDING AND EXTRACTION OF GIVEN BLOOD SUBSTANCES
PT76502A (en) Process for the preparation of n-glycosylated carboxamide derivatives with s stimulating effect of the body's inherent defences and their application for the preparation of pharmaceutical compositions having a stimulating effect of body's inherent defences
DE69333802D1 (de) Äusseres membranprotein von haemophilus
IL65201A0 (en) Composition for the treatment of epithelial injuries and process for the preparation thereof
ES2039193T3 (es) Polisacaridos inmunoestimulantes a partir de cultivos de celulas de echinea purpurea (linne) moench y de echinea angustifolia (de vandolle), su procedimiento de preparacion y composiciones farmaceuticas conteniendolos.
RU92016463A (ru) Применение производных цистина для изготовления лекарственных препаратов с иммуномоделирующим действием, фармацевтические композиции на их основе
DK235687D0 (da) Tilberedninger til syntese af prostaglandiner og hydroxyfedtsyrer i biologiske systemer og anvendelse deraf
DE68929388D1 (de) Aus Harn isolierte antikoagulierende Verbindung
IL72985A0 (en) Homogenous immune interferon fragment,its manufacture and pharmaceutical compositions containing it
BG96324A (bg) Фармакологично активно вещество врс, метод за неговото получаване и терапевтичното му приложение
NO163859C (no) Fremgangsmaate ved fremstilling av terapeutisk aktive succinylerte jernholdige proteiner.
FI953565A7 (fi) Uusi antikoagulanttikofaktoriaktiivisuus
BE900012A (fr) Nouveau peptide.
Bonilla et al. Comparative biochemistry and pharmacology of salivary gland secretions: II. Chromatographic separation of the basic proteins from some North American rattlesnake venoms
Guerranti et al. Characterization of the factor responsible for the antisnake activity of Mucuna pruriens seeds
YU176089A (sh) Postupak za pripremu supstancije bpc i supstancija bpc
NO173336C (no) Fremgangsm}te til isolering av basalmembranproteiner fra human- eller animalvev og anvendelse av det oppn}dde protein
DE3373978D1 (en) Composition for the care or treatment of the human skin
US4960756A (en) Lectin like protein substance, method of obtaining same and anti-tumor agent comprising same
ATE130192T1 (de) Verwendung von 15-deoxyspergualin als arzneimittel.
GB2003887A (en) Isolation of peptides from urine
KR920017663A (ko) 정제 진드기 알레르겐
IT1233005B (it) Anticorpo umano monoclonale, composizione terapeutica che lo contiene linea cellulare capace di produrre l'anticorpo, procedimento per la sua produzione